The company is an engineered cell therapy developer creating transformative medicines through ex vivo and in vivo cell engineering platforms. Its core business centers on two primary approaches: an ex vivo hypoimmune platform technology that enables allogeneic cell therapies to evade immune rejection without immunosuppression, with its lead candidate addressing type 1 diabetes through transplantation of engineered pancreatic islet cells; and an in vivo platform using proprietary fusogen technology to deliver genetic payloads directly to target cells, including a CAR T therapy for B cell cancers and autoimmune diseases. The company retains worldwide rights to its candidates and plans to generate revenue through product sales as its programs advance through clinical development toward commercialization, supported by partnerships with manufacturing organizations and a portfolio of licensed intellectual property.